Literature DB >> 19121927

Clinical, functional and biochemical changes during recovery from COPD exacerbations.

Angela Koutsokera1, Theodoros S Kiropoulos, Dimitrios J Nikoulis, Zoe D Daniil, Vassiliki Tsolaki, Kalliopi Tanou, Andriana I Papaioannou, Anastasios Germenis, Konstantinos I Gourgoulianis, Konstantinos Kostikas.   

Abstract

The pathways underlying chronic obstructive pulmonary disease exacerbations (ECOPD) remain unclear. This study describes the clinical, functional and biochemical changes during recovery from ECOPD. Thirty hospitalized patients with Anthonisen's type-I ECOPD were evaluated on days 0 (admission), 3, 10 and 40. A five-symptom score (TSS), performance status and quality of life were evaluated. Post-bronchodilator spirometry, blood gases, oxidative stress, C-reactive protein (CRP), serum amyloid-A (SAA), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and fibrinogen were also measured. Patients were classified as early- or late-recoverers, based on whether dyspnea had returned to pre-exacerbation level by day 10. Most clinical, functional and biochemical parameters improved during follow-up. CRP and IL-6 levels reduced on Day 3 (p<0.05), whereas SAA on Day 10 (p<0.01). TNF-alpha was reduced on Days 3 and 10, but on Day 40 its levels returned to baseline. Fibrinogen and WBC reduced only by day 40. TSS and dyspnea were correlated inversely with FEV(1) on days 3, 10 and 40. Although late-recoverers had lower FEV(1) on admission, none of the reported measurements on admission and day 3 predicted early recovery. During recovery from ECOPD, symptomatic improvement correlates only with post-bronchodilator FEV(1) whereas systemic inflammatory burden subsidence does not correlate with clinical and functional changes. Although late-recoverers have lower FEV(1) on admission, none of the measured parameters is able to predict early symptomatic recovery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19121927     DOI: 10.1016/j.rmed.2008.12.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  Correlation between decrease of CRP and resolution of airway inflammatory response, improvement of health status, and clinical outcomes during severe acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Ying Liang; Chun Chang; Hong Zhu; Ning Shen; Bei He; Wanzhen Yao
Journal:  Intern Emerg Med       Date:  2015-03-31       Impact factor: 3.397

2.  Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Authors:  Ken M Kunisaki; Mark T Dransfield; Julie A Anderson; Robert D Brook; Peter M A Calverley; Bartolome R Celli; Courtney Crim; Benjamin F Hartley; Fernando J Martinez; David E Newby; Alexa A Pragman; Jørgen Vestbo; Julie C Yates; Dennis E Niewoehner
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

3.  Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients.

Authors:  Ming Zhang; Yali Li; Xia Yang; Hu Shan; Qiuhong Zhang; Zongjuan Ming; Yingying Xie; Haijuan Chen; Yanqin Liu; Jie Zhang
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

4.  Changes of HMGB1 and sRAGE during the recovery of COPD exacerbation.

Authors:  Yonghong Zhang; Shaojun Li; Guizuo Wang; Dong Han; Xinming Xie; Yuanyuan Wu; Jing Xu; Jiamei Lu; Fengjuan Li; Manxiang Li
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

Review 5.  Oxidative Stress Biomarkers in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review.

Authors:  Elisabetta Zinellu; Angelo Zinellu; Alessandro G Fois; Maria Carmina Pau; Valentina Scano; Barbara Piras; Ciriaco Carru; Pietro Pirina
Journal:  Antioxidants (Basel)       Date:  2021-04-29

6.  Lung function decline is associated with serum uric acid in Korean health screening individuals.

Authors:  Kyung-Min Ahn; Suh-Young Lee; So-Hee Lee; Sun-Sin Kim; Heung-Woo Park
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

7.  Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays.

Authors:  José L López-Campos; Elena Arellano; Carmen Calero; Ana Delgado; Eduardo Márquez; Pilar Cejudo; Francisco Ortega; Francisco Rodríguez-Panadero; Ana Montes-Worboys
Journal:  BMC Med Res Methodol       Date:  2012-03-31       Impact factor: 4.615

8.  Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease.

Authors:  Jan Willem H Kocks; Jan Willem K van den Berg; Huib A M Kerstjens; Steven M Uil; Judith M Vonk; Ynze P de Jong; Ioanna G Tsiligianni; Thys van der Molen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-06-06

Review 9.  Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease.

Authors:  Annelyse Duvoix; Jenny Dickens; Imran Haq; David Mannino; Bruce Miller; Ruth Tal-Singer; David A Lomas
Journal:  Thorax       Date:  2012-06-28       Impact factor: 9.139

10.  Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Patricia García-Sidro; Alonso Fernández-Nistal; María Jesús Buendía; María José Espinosa de los Monteros; Jesús Molina
Journal:  Health Qual Life Outcomes       Date:  2013-08-29       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.